Altimmune Inc
NASDAQ:ALT 1:52:14 PM EDT
| Market Cap (Intraday) | 306.78M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.10 |
| 50-Day MA | $9.57 |
| 200-Day MA | $11.92 |
Altimmune Inc Stock, NASDAQ:ALT
910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878
United States of America
Phone: +1.240.654.1450
Number of Employees: 43
Description
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is developing pemvidutide (ALT-801), a novel, GLP-1/glucagon dual agonist for the treatment of obesity and non-alcoholic steatohepatitis (NASH), and HepTcell(TM), an immunotherapeutic candidate for patients chronically infected with the hepatitis B virus (HBV). The company was founded in 1997 and is headquartered in Gaithersburg, MD.